Question 1

What is PACLITAXEL PROTEIN-BOUND PARTICLES used for?

Accepted Answer

PACLITAXEL PROTEIN-BOUND PARTICLES (brand name Paclitaxel protein-bound particles) is a Chemotherapy indicated for 1 INDICATIONS AND USAGE Paclitaxel is a microtubule inhibitor indicated for the treatment of: Metastatic breast cancer, as first-line treatment in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy. ( 1.2 ) Metastatic adenocarcinoma of the pancreas as first-line treatment.

Question 2

How does PACLITAXEL PROTEIN-BOUND PARTICLES work?

Accepted Answer

PACLITAXEL PROTEIN-BOUND PARTICLES works through the following mechanism: 12.1 Mechanism of Action Paclitaxel is a microtubule inhibitor that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. Paclitaxel induces abnormal arrays or "bundles" of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis..

Question 3

What are the most common side effects of PACLITAXEL PROTEIN-BOUND PARTICLES?

Accepted Answer

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for PACLITAXEL PROTEIN-BOUND PARTICLES. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Question 4

Is PACLITAXEL PROTEIN-BOUND PARTICLES the same as Paclitaxel protein-bound particles?

Accepted Answer

Paclitaxel protein-bound particles is a brand name for PACLITAXEL PROTEIN-BOUND PARTICLES. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

PACLITAXEL PROTEIN-BOUND PARTICLES

Mechanism of Action

Indications

FDA Warnings

Known Side Effects

Community Discussions

Primary sources

Compare With

Formulations